| Similar Articles |
|---|
 |
The Motley Fool
July 23, 2008
Brian Lawler |
No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results.   |
The Motley Fool
January 29, 2010
Brian Orelli |
Icahn Back to Batter Biogen The old guy has tenacity. |
The Motley Fool
January 25, 2010
Brian Orelli |
Tysabri Updates: All You Have to Do Is Ask Biogen Idec is willing to hook medical doctors up with an automatic monthly update of the number of progressive multifocal leukoencephalopathy cases for people taking it and Elan's multiple sclerosis drug, Tysabri. |
The Motley Fool
May 13, 2009
Brian Orelli |
Icahn's an Energizer Pit Bull He keeps going and doesn't let go. |
The Motley Fool
October 22, 2008
Brian Orelli |
Biogen Has Growth in all the Wrong Places Biogen Idec saw substantial growth in the third quarter, but apparently it's coming from all the wrong places. |
The Motley Fool
October 30, 2008
Brian Orelli |
Not What the Doctor Ordered Biogen reports a third case of a deadly brain disorder since their multiple sclerosis drug Tysabri made its return. |
The Motley Fool
July 17, 2009
Brian Orelli |
Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva. |
The Motley Fool
January 21, 2011
Brian Orelli |
Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down. |
The Motley Fool
February 7, 2008
Brian Lawler |
Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition. |
The Motley Fool
October 27, 2010
Brian Orelli |
Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan. |
The Motley Fool
January 12, 2010
Brian Orelli |
Tysabri: It's a Blockbuster! Yawn. So What? Is it really a big deal that Tysabri finally achieved blockbuster status? |
The Motley Fool
June 30, 2009
Brian Orelli |
Here We Go Again With Tysabri The number of patients on Biogen Idec's and Elan's multiple sclerosis drug, Tysabri, that have gotten progressive multifocal leukoencephalopathy since the drug was reintroduced to the market has reached double digits. |
The Motley Fool
February 22, 2011
Brian Orelli |
Biogen and Elan's Growing Problem More cases of potentially lethal PML. |
The Motley Fool
August 26, 2008
Brian Lawler |
FDA Changes Course for Elan and Biogen Idec The agency takes a different tack with one of the partnership's top drugs. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
January 5, 2010
Brian Orelli |
Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out. |
The Motley Fool
June 4, 2009
Brian Orelli |
Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price. |
The Motley Fool
October 26, 2009
Brian Orelli |
For Tysabri, 23 Is 10 Too Many The side effect rate is important. |
The Motley Fool
February 2, 2011
Brian Orelli |
A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker. |
The Motley Fool
October 20, 2009
Brian Orelli |
All Tysabri, All the Time Biogen needs to focus on its most potential-packed drug. |
The Motley Fool
February 10, 2009
Brian Orelli |
Elan Needs a Face-Lift Elan is in need of a serious makeover. The company has been beaten down severely, but there's still plenty of beauty in this pharma. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
March 26, 2009
Brian Orelli |
R&D Your Way to Higher Sales Biogen is trying to lower side effects to increase sales. |
The Motley Fool
November 18, 2008
Brian Orelli |
Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere. |
The Motley Fool
March 23, 2010
Brian Orelli |
Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next? |
The Motley Fool
January 30, 2009
Brian Orelli |
Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%. |
The Motley Fool
September 15, 2008
Brian Orelli |
Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company. |
The Motley Fool
April 17, 2009
Brian Orelli |
When Revenue Trumps Earnings Biogen grows earnings, but what does that say about the future? |
The Motley Fool
October 31, 2011
Brian Orelli |
When You've Got It, You've Got It Biogen keeps its good-news streak going. |
The Motley Fool
December 13, 2007
Brian Lawler |
Biogen Can't Find a Buyer After formally putting itself up for sale two months ago, Biogen Idec announces that it can't find any takers. |
The Motley Fool
March 11, 2005
Karl Thiel |
Better Times at Biogen IDEC Is now the time to buy this pharmaceutical? |
The Motley Fool
February 10, 2010
Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool
March 8, 2005
Charly Travers |
After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market. |
The Motley Fool
April 25, 2008
Brian Lawler |
Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
August 20, 2010
Brian Orelli |
This Billionaire Likes Biotech. Should You? It depends on how much you trust management. |
The Motley Fool
October 24, 2007
Brian Lawler |
Biogen's Brisk Business Following a rumor-filled and busy couple of weeks, Biogen releases its third-quarter financial results. |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
The Motley Fool
February 23, 2010
Brian Orelli |
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. |
The Motley Fool
April 11, 2008
Brian Orelli |
Teva Tugs at Both Ends of the MS String Teva tries to get multiple sclerosis patients to switch to its drug. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
October 1, 2009
Anders Bylund |
Why I'm Invested in Tysabri and Elan This Motley Fool analyst has investigated Elan both as an investor and a patient. What's his verdict on the company? |
The Motley Fool
January 29, 2008
Brian Lawler |
Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec. |
The Motley Fool
October 16, 2007
Brian Lawler |
Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note. |
The Motley Fool
April 24, 2009
Brian Orelli |
Great Drugs Not Living Up to Their Potential How well a drug works is not the most important thing to consider when investing. Drugs that work don't always become blockbusters. |
The Motley Fool
June 11, 2008
Brian Lawler |
He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head. |
The Motley Fool
March 31, 2005
Stephen D. Simpson |
Strike Three for Tysabri A third confirmed case of PML all but eliminates Tysabri's potential as a blockbuster drug. For Elan and Biogen investors, the news continues to sting. |
BusinessWeek
March 21, 2005
Catherine Arnst |
On The Hot Seat At Biogen How Biogen CEO Jim Mullen managed a drug crisis after alarming news broke that the multiple sclerosis drug Tysabri may cause a deadly brain infection. |
The Motley Fool
May 26, 2005
Stephen D. Simpson |
Elan Holds Its Ground Elan clearly isn't throwing in the towel on Tysabri, but its fate is not solely in the company's hands. If you're pinning your hopes on a full return on this drug, you might be signing on for more risk than you really want. |
The Motley Fool
September 4, 2009
Brian Orelli |
The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up. |
